Search This Blog

Friday, October 30, 2026

Sanofi beats Q3 expectations on business EPS and revenue, raises full-year outlook

 

 to low-teens sales and mid-teens EPS growth

  • Strong Dupixent growth drove Sanofi's Q3 business EPS and revenue performance above expectations.
  • Full-year outlook now calls for low-teens sales growth and mid-teens EPS growth at constant exchange rates.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)